literature

HIV mutation literature information.

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.

PMID: 31976534 2020 The Journal of antimicrobial chemotherapy

Abstract: RESULTS: The frequencies of doravirine-associated resistance mutations (total dataset versus NNRTI-failing patients) were: V106A/M, 0.8% versus 2.6%; V108I, 3.3% versus 9.2%; Y188L, 1.2% versus 2.6%; G190S, 0.3% versus 2.1%; F227C/L/V, 0.5% versus 1.8%; M230I/L, 2.8% versus 0%; L234I, 0.1% versus 0.5%; K103N + Y181C, 3.9% versus 3.9%; K103N + P225H, 2.9% versus 4.7%; and K103N + L100I, 1.7% versus 3.9%, with a significantly higher proportion of these mutations in the

Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017).

PMID: 31922125 2020 EClinicalMedicine

Result: Furthermore, a higher percentage of V106A/M (13.29%) in ART-treated individuals was observed in Central China than other regions.

Table: V106A/M

Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen.

PMID: 33014372 2020 SAGE open medicine

Table: V106A

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens.

PMID: 30863788 2019 Open forum infectious diseases

Introduction: Studies of drug resistance mutations (DRMs) in plasma virus ribonucleic acid (RNA) by Sanger consensus sequencing frequently identify mutations associated with nonnucleoside reverse-transcriptase inhibitors (NNRTIs); most often K103N, followed by G190S, V106A/M, Y181C, Y188L, and P225H.

Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa.

PMID: 30430843 2019 AIDS research and human retroviruses

Abstract: The most prevalent SDRMs were K103NS (7.5%), M184VI (2.4%), and V106AM (1.4%).

Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.

PMID: 30769200 2019 International journal of antimicrobial agents

Abstract: High-level DOR resistance was defined as detection of any of Y188L, M230L, G190E, V106A/M+F227L, and V106A/M+L234I.

Abstract: Intermediate DOR resistance was defined as detection of any of V106A/M, Y188C/H, V108I, and K103N+P225H.

Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.

PMID: 30624934 2019 Journal of medicinal chemistry

Conclusion: For double mutant HIV-1 strains F227L+V106A and RES056, both inhibitors displayed comparable activities with those of ETV.

Result: As noted above, 13c2 can inhibit single (L100I, K103N, Y181C, Y188L, E138K) and double (F227+V106A) mutated HIV-RT variants (see Figure S3 for the location of these mutations).

Result: For F227L+V106A, 13c3 (EC50 = 7.2 nM) showed the highest potency and was 2.7-fold more potent than ETV (EC50 = 19.7 nM).

Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China.

PMID: 30621727 2019 Virology journal

Discussion: In this study, the occurrence rates for K103 N/R/S, G190A, and V106A were higher than that for Y181C/I/V; however, after a long period, the Y181C/I/V and K103 N/R/S mutations showed a greater prevalence.

Discussion: Previous studies have performed adaptive sequencing of subjects receiving NNRTIs, and confirmed that the most common mutations are as follows: Y181C/I/V > K103 N/R/S > G190A > V106A.

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.

PMID: 30476106 2019 The Journal of antimicrobial chemotherapy

Abstract: We studied the prevalence of doravirine resistance-associated mutations previously identified in vitro: V106A/M, V108I, Y188L, V190S, H221Y, F227C/L/V, M230I/L, L234I, P236L, Y318F and K103N/Y181C.

Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.

PMID: 31751428 2019 PloS one

Result: The most common patterns among ART-experience patients were K103N only or in combination with P225H or V106A (9.8%, 4/41), Y181C only or in combination with V108I (9.0%, 4/41) and V179E (4.9%, 2/41).

Table: V106A

Browser Board

Co-occurred Entities

Filtrator